US FDA approves Sanofi's genetic disorder drug
US FDA approves Sanofi's genetic disorder drug Nov 18 xx (Reuters) - The US FDA on Wednesday approved Sanofi's SASY.PA oral drug venglustat, making it the first treatment for a type of rare genetic condition that affects the brain and nervous system, the health regulator said.
(Reporting by Kamal Choudhury in Bengaluru and Bhanvi Satija in London; Editing by Sahal Muhammed)
Recent news on Regeneron Pharmaceuticals
See all newsCorrected: UPDATE 2-US FDA approves Regeneron's drug for generalized myasthenia gravis (November 18)
Refile: US FDA approves Regeneron's drug for generalized myasthenia gravis
Brief: Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing
US FDA approves Sanofi's genetic disorder drug
Brief: Regeneron Pharmaceuticals Said Single Administration Of CIDEB(siRNA) Led To Reductions In Liver Fat Up To 80% That Were Sustained Through 36 Weeks